FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel
pharmaphorum
DECEMBER 9, 2020
The most common adverse reactions seen in a trial cohort of 38,000 patients were at injection sites (84.1%) followed by fatigue (62.9%) and headache (55.1%), and serious adverse reactions occurred in 0% to 4.6% of participants.
Let's personalize your content